AI pricing tools promise the one thing every business owner wants: optimized margins on autopilot.
Here's what most people adopting them don't realize. The same tool quietly setting your prices may be coordinating them — with your competitors.
Algorithmic collusion is becoming the new antitrust frontier. When multiple businesses feed their pricing decisions to the same AI, the algorithm can converge on prices no one explicitly agreed to. You never shook hands in a back room. But regulators increasingly aren't convinced that distinction protects you.
For a small business owner, that's two kinds of risk wrapped into one tool.
Legal risk — you may be participating in coordinated pricing without ever intending to.
Reputational risk — and this is the one founders underestimate. "We let the algorithm decide" is not a story your customers, your press, or your board will forgive. Your brand is your promise. Outsourcing pricing to a black box you can't explain is a promise you can't keep.
I'm not anti-AI. I build with it every day. But I've watched founders adopt powerful tools the same way for 25 years: fast, blindly, and without asking who's accountable when it goes wrong.
The strategic move isn't to avoid AI. It's to stay the decision-maker.
Three questions worth asking before you turn any pricing tool on:
- Can I explain, in plain language, how this sets my prices?
- Does it rely on competitor data I shouldn't have a window into?
- If a regulator or a reporter asked me about it tomorrow, would my answer hold up?
AI should amplify your judgment, not replace your accountability. The leaders who win the next decade won't be the ones who automated the most. They'll be the ones who stayed responsible for the decisions that actually mattered.
For those of you leading high-stakes initiatives: where are you drawing the line between what AI gets to decide and what you stay accountable for? …more
AI Regulation
Work by Michael Ashley · Everyone on AI Regulation
Impressive to see Lilly launch LillyPod, the first NVIDIA DGX SuperPOD with DGX B300 systems. Is it even possible to compete in this space anymore? My experience launching startups and programs says yes, if you lean into startup advantages: pick a narrow, clinically meaningful problem you can validate fast; secure or partner for unique data and domain workflows; design pilots that align with regulatory and procurement paths. If you are building in this space, send me a message. #AIinPharma
https://blogs.nvidia.com/blog/lilly-ai-factory-live/ …more
Controversy can be a growth signal if you plan for it. Anthropic was aligned with their values, they faced regulatory pushback, and customers rewarded them.
Company culture and values matter more than you think. Here are some tips for founders:
1) Define non-negotiables and why they matter to users.
2) Build a response playbook for regulatory or PR scrutiny.
3) Turn backlash into learnings: capture why users care and make sure you're aligned ethically and strategically.
Send me a message if you want to map a launch plan. #product
https://www.santacruzworks.org/news/how-to-boost-your-app-downloads-get-banned-by-trump …more
Channel names and logos are trademarks of their respective owners.